Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.
Heinemann
V
V
Department of Internal Medicine, Hematology/Oncology, Klinikum Grosshadern, University of Munich, F.R.G.
Jehn
U
U
D001085:Arabinofuranosylcytosine Triphosphate / Q000378:metabolism; D001692:Biological Transport; D003561:Cytarabine / Q000008:administration & dosage / Q000378:metabolism / Q000627:therapeutic use*; D003641:Deamination; D004334:Drug Administration Schedule; D004351:Drug Resistance; D006801:Humans; D007262:Infusions, Intravenous / Q000379:methods; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000378:metabolism; D010766:Phosphorylation; D012008:Recurrence
D003561:Cytarabine; D001085:Arabinofuranosylcytosine Triphosphate